RHD and Thromboembolism: Eligible patients were those at high risk for platelet transfusion, identified by risk prediction score or clinician judgment, excluding female patients aged 18 to 55 years who were rhesus D (RhD) negative or with unknown RhD status and patients with coagulopathy or prior thromboembolism.